Skip to main content
DrugPrice

Lovenox vs Pradaxa

Side-by-side cost comparison based on Medicare Part D data

Lovenox costs 48% less per claim than Pradaxa ($94.00 vs $180.00). A generic version of Lovenox is also available, which may reduce costs further.

Cost Per Claim

Lovenox$94.00
Pradaxa$180.00

Medicare Spending

Lovenox$456.0M
Pradaxa$876.0M

Beneficiaries

Lovenox580,000
Pradaxa580,000

Annual Cost Per Patient

Lovenox$786.00
Pradaxa$1,510.00

Full Comparison

MetricLovenoxPradaxa
Avg Cost Per Claim$94.00$180.00
Total Medicare Spending$456.0M$876.0M
Total Beneficiaries580,000580,000
Total Claims4,860,0004,860,000
Annual Cost/Patient$786.00$1,510.00
Year-over-Year Change-14.2%-9.8%
Generic AvailableYesYes
Patent ExpirationJan 31, 2023Jan 31, 2023
ManufacturerSanofiBoehringer Ingelheim
ConditionBlood ClotsBlood Clots
Generic NameEnoxaparinDabigatran

Lovenox vs Pradaxa: What the Data Shows

Lovenox (Enoxaparin) and Pradaxa (Dabigatran) are both used to treat blood clots. Based on Medicare Part D data, Lovenox costs $94.00 per claim, which is 48% less than Pradaxa at $180.00 per claim.

Medicare spent $456.0M on Lovenox and $876.0M on Pradaxa. In terms of patient reach, Pradaxa serves more beneficiaries (580,000 vs 580,000).

Year-over-year spending changed -14.2% for Lovenox and -9.8% for Pradaxa.

Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.

Frequently Asked Questions

Lovenox is cheaper at $94.00 per claim, compared to $180.00 for Pradaxa. That makes Lovenox about 48% less expensive per claim based on Medicare Part D data.

Yes, both Lovenox and Pradaxa are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.

Both drugs have generic versions available. Generic Enoxaparin and generic Dabigatran can offer significant cost savings — typically 80-95% less than the brand name.

Medicare Part D spent $456.0M on Lovenox covering 580,000 beneficiaries, and $876.0M on Pradaxa covering 580,000 beneficiaries.

Explore Further

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.